Results 81 to 90 of about 1,111,262 (342)

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

'The Voice of Home' [PDF]

open access: yes, 2012
Page number(s) as given: p.561 ...

core  

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

'Foreign Exiles in England' [PDF]

open access: yes, 2012
Page number(s) as given: pp.316 ...

core  

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Correction: “Ahmed H. Touny, Mahmoud M. Saleh, Enhanced Methanol Oxidation on Nanoporous Nickel Phosphate Modified Platinum Electrode in Alkaline Solution” [Int. J. Electrochem. Sci., 13 (2018) 1042 - 1050]

open access: yesInternational Journal of Electrochemical Science, 2018
In page 1049 in the Acknowledgement part. The project number was written as #100754 The correction is: The project # 100759.
Ahmed. H. Touny, Mahmoud. M. Saleh
doaj   +1 more source

'Strangers Yet' [PDF]

open access: yes, 2012
Page number(s) as given: pp.306 ...

core  

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

'A Mother's Heart' [PDF]

open access: yes, 2012
Page number(s) as given: pp.97 ...

core  

Home - About - Disclaimer - Privacy